Recent Articles By The Author
The first-quarter reports from Camping World, Esperion Therapeutics and BioDelivery Sciences were impressive amid coronavirus disruption.
Merger activity is picking up this week in the biotechnology sector and these four promising companies would be good buyout candidates.
Eagle Pharmaceuticals, Biohaven Pharmaceuticals and Acadia Pharmaceuticals are names to consider on a 10% move down in equities.
Massive unemployment, reduced consumer spending and uncertainty around state reopening plans favor a U-shaped recovery from the coronavirus crisis.
Quotient Limited and Redhill Biopharma could deliver for shareholders, while Novavax Inc. and Inovio Pharmaceuticals may not in the end.
It is worth tracking these three names.
Retail and real estate already were undergoing change and that process only will be accelerated by differences in how we live amid the coronavirus.
Flexion Therapeutics and BioDelivery Sciences International have promising products that should do well once the fixation on Covid-19 treatments wanes.
Simply Good Foods and Myovant Sciences looked poised to see their shares rise over the longer term.
I never understood why my state of Florida, with vastly fewer deaths, is on the same sort of lockdown as New York.